Antifibrotic agents, namely nintedanib and pirfenidone, are the only medications approved by the US Food and Drug Administration for the treatment of IPF. Although these drugs are not curative, they have been shown to slow the fibrotic changes associated with IPF. Nintedanib, a tyrosine kinase receptor blocker, preserves lung function by slowing fibrogenesis, and also may increase the length of time to a patient's first AE-IPF. Pirfenidone, a pyridone derivative recommended for mild to moderate IPF, slows fibrogenesis by inhibiting collagen formation. The updated American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society IPF guidelines include a conditional recommendation for antifibrotic therapy.
Anticoagulants, antibiotics, and antihypertensives are not used in treatment of IPF.
Learn more about antifibrotic agents in the treatment of IPF.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Guy W. Soo Hoo, Zab Mosenifar. Fast Five Quiz: Idiopathic Pulmonary Fibrosis Treatment - Medscape - May 12, 2022.